STEVEN GROSSMAN 2/11/20 STEVEN GROSSMAN 2/11/20 Alliance Issues Analysis of President's FY 21 Request for FDA Funding Read More Analysis and Commentary STEVEN GROSSMAN 2/7/20 Analysis and Commentary STEVEN GROSSMAN 2/7/20 Shuren Fills Alliance in on Fast-Moving Science and CDRH Needs Read More Advocacy at a Glance STEVEN GROSSMAN 2/7/20 Advocacy at a Glance STEVEN GROSSMAN 2/7/20 Upcoming Alliance Events Read More Analysis and Commentary STEVEN GROSSMAN 2/1/20 Analysis and Commentary STEVEN GROSSMAN 2/1/20 FDA's FY 21 Appropriation: What's Happening When? Read More Advocacy at a Glance STEVEN GROSSMAN 2/1/20 Advocacy at a Glance STEVEN GROSSMAN 2/1/20 Upcoming Hill Opportunity for Alliance Members Read More Analysis and Commentary STEVEN GROSSMAN 1/25/20 Analysis and Commentary STEVEN GROSSMAN 1/25/20 Alliance Learns About CBER Priorities for 2020 and Beyond Read More Advocacy at a Glance STEVEN GROSSMAN 1/25/20 Advocacy at a Glance STEVEN GROSSMAN 1/25/20 Notes from the Alliance Meeting with CBER Director, Dr. Peter Marks Read More Analysis and Commentary STEVEN GROSSMAN 1/17/20 Analysis and Commentary STEVEN GROSSMAN 1/17/20 Hill Day and Other Upcoming Alliance Advocacy Initiatives Read More Advocacy at a Glance STEVEN GROSSMAN 1/17/20 Advocacy at a Glance STEVEN GROSSMAN 1/17/20 The Lull Before FY 21 Appropriations, But Hardly Quiet in Washington Read More Analysis and Commentary STEVEN GROSSMAN 1/10/20 Analysis and Commentary STEVEN GROSSMAN 1/10/20 FDA Is Its People Read More Advocacy at a Glance STEVEN GROSSMAN 1/10/20 Advocacy at a Glance STEVEN GROSSMAN 1/10/20 Before Focusing on FY 21 Funding: A Recap of FY 20 Read More Analysis and Commentary STEVEN GROSSMAN 12/20/19 Analysis and Commentary STEVEN GROSSMAN 12/20/19 Success Again in 2019 ... Building Support for 2020 Read More Advocacy at a Glance STEVEN GROSSMAN 12/20/19 Advocacy at a Glance STEVEN GROSSMAN 12/20/19 FY 20 Appropriations: Headed to the President for His Signature Read More Analysis and Commentary STEVEN GROSSMAN 12/16/19 Analysis and Commentary STEVEN GROSSMAN 12/16/19 FDA's "Appropriation Fate" Is Evaluated on a Daily Basis Read More Advocacy at a Glance STEVEN GROSSMAN 12/16/19 Advocacy at a Glance STEVEN GROSSMAN 12/16/19 Agreement in Principle on All 12 Appropriations Bills. House Slated to Vote Tuesday Read More Analysis and Commentary STEVEN GROSSMAN 12/8/19 Analysis and Commentary STEVEN GROSSMAN 12/8/19 Three Key Questions ... and the Answers Read More Advocacy at a Glance STEVEN GROSSMAN 12/8/19 Advocacy at a Glance STEVEN GROSSMAN 12/8/19 The 302(b) Allocations Deal: Fixes Some, But Not All, of the Problems Read More Analysis and Commentary STEVEN GROSSMAN 11/22/19 Analysis and Commentary STEVEN GROSSMAN 11/22/19 Time to Talk Turkey ... Once Again Read More Advocacy at a Glance STEVEN GROSSMAN 11/22/19 Advocacy at a Glance STEVEN GROSSMAN 11/22/19 Continuing Resolution Extends Funding through December 20 Read More STEVEN GROSSMAN 11/21/19 STEVEN GROSSMAN 11/21/19 Senate HELP Committee Interviews Stephen Hahn, MD Read More Newer Posts Older Posts
STEVEN GROSSMAN 2/11/20 STEVEN GROSSMAN 2/11/20 Alliance Issues Analysis of President's FY 21 Request for FDA Funding Read More
Analysis and Commentary STEVEN GROSSMAN 2/7/20 Analysis and Commentary STEVEN GROSSMAN 2/7/20 Shuren Fills Alliance in on Fast-Moving Science and CDRH Needs Read More
Advocacy at a Glance STEVEN GROSSMAN 2/7/20 Advocacy at a Glance STEVEN GROSSMAN 2/7/20 Upcoming Alliance Events Read More
Analysis and Commentary STEVEN GROSSMAN 2/1/20 Analysis and Commentary STEVEN GROSSMAN 2/1/20 FDA's FY 21 Appropriation: What's Happening When? Read More
Advocacy at a Glance STEVEN GROSSMAN 2/1/20 Advocacy at a Glance STEVEN GROSSMAN 2/1/20 Upcoming Hill Opportunity for Alliance Members Read More
Analysis and Commentary STEVEN GROSSMAN 1/25/20 Analysis and Commentary STEVEN GROSSMAN 1/25/20 Alliance Learns About CBER Priorities for 2020 and Beyond Read More
Advocacy at a Glance STEVEN GROSSMAN 1/25/20 Advocacy at a Glance STEVEN GROSSMAN 1/25/20 Notes from the Alliance Meeting with CBER Director, Dr. Peter Marks Read More
Analysis and Commentary STEVEN GROSSMAN 1/17/20 Analysis and Commentary STEVEN GROSSMAN 1/17/20 Hill Day and Other Upcoming Alliance Advocacy Initiatives Read More
Advocacy at a Glance STEVEN GROSSMAN 1/17/20 Advocacy at a Glance STEVEN GROSSMAN 1/17/20 The Lull Before FY 21 Appropriations, But Hardly Quiet in Washington Read More
Analysis and Commentary STEVEN GROSSMAN 1/10/20 Analysis and Commentary STEVEN GROSSMAN 1/10/20 FDA Is Its People Read More
Advocacy at a Glance STEVEN GROSSMAN 1/10/20 Advocacy at a Glance STEVEN GROSSMAN 1/10/20 Before Focusing on FY 21 Funding: A Recap of FY 20 Read More
Analysis and Commentary STEVEN GROSSMAN 12/20/19 Analysis and Commentary STEVEN GROSSMAN 12/20/19 Success Again in 2019 ... Building Support for 2020 Read More
Advocacy at a Glance STEVEN GROSSMAN 12/20/19 Advocacy at a Glance STEVEN GROSSMAN 12/20/19 FY 20 Appropriations: Headed to the President for His Signature Read More
Analysis and Commentary STEVEN GROSSMAN 12/16/19 Analysis and Commentary STEVEN GROSSMAN 12/16/19 FDA's "Appropriation Fate" Is Evaluated on a Daily Basis Read More
Advocacy at a Glance STEVEN GROSSMAN 12/16/19 Advocacy at a Glance STEVEN GROSSMAN 12/16/19 Agreement in Principle on All 12 Appropriations Bills. House Slated to Vote Tuesday Read More
Analysis and Commentary STEVEN GROSSMAN 12/8/19 Analysis and Commentary STEVEN GROSSMAN 12/8/19 Three Key Questions ... and the Answers Read More
Advocacy at a Glance STEVEN GROSSMAN 12/8/19 Advocacy at a Glance STEVEN GROSSMAN 12/8/19 The 302(b) Allocations Deal: Fixes Some, But Not All, of the Problems Read More
Analysis and Commentary STEVEN GROSSMAN 11/22/19 Analysis and Commentary STEVEN GROSSMAN 11/22/19 Time to Talk Turkey ... Once Again Read More
Advocacy at a Glance STEVEN GROSSMAN 11/22/19 Advocacy at a Glance STEVEN GROSSMAN 11/22/19 Continuing Resolution Extends Funding through December 20 Read More
STEVEN GROSSMAN 11/21/19 STEVEN GROSSMAN 11/21/19 Senate HELP Committee Interviews Stephen Hahn, MD Read More
